Anaemia was found in 21.2% (51/241) of the IBD patients and more frequently in patients from RC as compared to GP and healthy controls (28.8% vs. 12.9% vs. 3.4%; P<0.01). IBD patients from RC suffered more frequently from active disease compared to IBD patients in GP (36% vs. 23%, P=0.032). Supplementation therapy
(iron, vitamine B12, folic acid) was performed in 40% of anaemic IBD patients in GP as compared to 43% in RC.
Conclusions: Anaemia is a common complication in patients with IBD and significantly more KPT-8602 nmr prevalent in patients from referral centres as compared to patients from gastroenterologic practices. Physicians treating IBD patients should pay attention to the presence of anaemia and ensure sufficient supplementation therapy. (C) 2010 European AZ 628 clinical trial Crohn’s and Colitis Organisation. Published by Elsevier B.V. All rights reserved.”
“Synthesis of the 6-hydroxy-7-methyl analog of typharin (8-dihydroxy-3-styryl-3,4-dihydroisocoumarin) isolated from the rhizomes of Typha capensis has been described. Direct condensation of 3,5-dimethoxy-4-methylhomophthalic
acid (1) with cinnamoyl chloride at elevated temperature under inert conditions afforded 6,8-dihydroxy-7-methyl-3-styrylisocoumarin (2). Hydrolysis of isocoumarin to keto acid (3) followed by reduction and cyclodehydration of hydroxy acid analog (4) afforded (+/-)-6,8-dimethoxy-3-(4-methoxyphenyl)-3,4-dihydroisocoumarin (5). Demethylation of the latter using anhydrous aluminum chloride/ethane thiol furnished the title isocoumarin (6). Compounds (1-6) GSK872 were screened for in vitro antibacterial activity against a representative panel of Gram-positive and Gram-negative bacteria using levofloxacin as the reference drug.”
“Two
new compounds lyciumtetraterpenic hexaarabinoside (1) and tetraterpenyl hexaarabinoside (2), along with two known compounds, were isolated from the methanol extract of the fruits of Lycium chinense Miller (Solanaceae), and their structures have been elucidated as 6-(1,1,5-trimethyl-5-hydroxycyclohexanyl)-6-(1,1,5-trimethyl-2-hydroxycyclohexanyl)-9,13,9,13-tetramethyloctadec-7,9,11,13,15,7,9,11,13-nonene-5-D-arabinopyranosyl(2a1b)–D-arabinopyranosyl-(2b1c)–D-arabinopyranosyl-2–D-arabinopyranosyl-(2d1e)–D-arabinopyranosyl-(2e1f)–D-arabinopyranoside (1) and 1(6),11(12),13(14),1(6),11(12),13(14)-dodecahydro–caroten-4,4-diol-4-L-arabinopyranosyl-(2a1b)–L-arabinopyranosyl-(2b1c)–D-arabinopyranosido-4-L-arabinopyranosyl-(2d1e)–L-arabinopyranosyl-(2e1f)–D-arabinopyranoside (2) on the basis of spectral data analysis and chemical reactions.”
“Background and Aims: One of the major symptoms of chronic inflammatory bowel diseases is anemia. The two most common diseases are Crohn’s disease and ulcerative colitis.